On August 22, 2019 Universal Health Services, Inc. (NYSE: UHS) reported that Steve Filton, Executive Vice President and Chief Financial Officer will present at the following conferences (Press release, Universal Health Services, AUG 22, 2019, View Source [SID1234538946]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, September 4, 2019 at 10:50 a.m. (ET) at the Baird’s 2019 Global Healthcare Conference in New York, New York.

Thursday, September 5, 2019 at 9:45 a.m. (ET) at the 2019 Wells Fargo Healthcare Conference in Boston, Massachusetts.

Live audio webcasts of the presentations will be available on the Company’s website (www.uhsinc.com). For those unable to listen to the live webcast, replays of the presentations will be available on the Company’s website for 90 days following the conferences.

Headquartered in King of Prussia, PA, UHS has more than 87,000 employees and through its subsidiaries operates 350 inpatient acute care hospitals and behavioral health facilities and 37 outpatient and other facilities located in 37 states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information on the Company, visit our web site: View Source

On August 21, 2019 PER Global, a worldwide leading resource for continuing medical education (CME), reported that it will host the live CME-accredited Medical Crossfire: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies, adjunct to the IASLC 2019 World Conference on Lung Cancer (Press release, Physicians’ Education Resource, AUG 21, 2019, View Source [SID1234538912]). The program will take place on Sunday, 08 Sept. 2019 from 11:30 a.m. to 13:30 p.m. in Hall 6 at Fira de Barcelona – Gran Via venue in Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Medical Crossfire will be chaired by Naiyer A. Rizvi, M.D., professor of medicine; director, thoracic oncology; co-director, cancer immunotherapy program; and the Price Family Professor of Medicine, Columbia University Irving Medical Center.

"The contemporary treatment of NSCLC requires the coordination and cooperation of the full treatment team," said Phil Talamo, president of PER Global. "Through our Medical Crossfire format, we will bring together pathology, medical oncology, and radiation oncology to foster a detailed discussion of the current and future of care for patients with non-small cell lung cancer (NSCLC)."

The variety of treatment options for patients with NSCLC continue to evolve, further complexifying the treatment landscape for this multifaceted illness. This program will feature a multidisciplinary faculty, world-renowned experts in medical oncology, radiation oncology and surgery. Current standards of care in patients with unresectable stage 3 NSCLC will be addressed, including the current and future roles of biomarkers and management of immune-related adverse events. Throughout the program, expert Medical Crossfire discussion panels will illustrate how experts address challenges in the implementation of immunotherapy for patients with locally advanced NSCLC.

The faculty panel includes the following experts:

Keith M. Kerr, FRCPath, consultant pathologist, department of pathology, Aberdeen Royal Infirmary, and professor of pulmonary pathology, Aberdeen University Medical School.
Suresh Senanm, MRCP, FRCR, Ph.D., professor of clinical experimental radiotherapy, department of radiation oncology. Amsterdam University Medical Center.
Rolf A. Stahel, M.D., professor in the oncology clinic, University Hospital Zurich.
This live activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 2 European CME credits for physicians. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. For more information and to register, click here.

On August 21, 2019 Anixa Biosciences, Inc presented the corporate presentation (Presentation, Anixa Biosciences, AUG 21, 2019, View Source [SID1234538929]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 21, 2019 Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Bayer’s new product Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) (Press release, Onco360, AUG 21, 2019, View Source [SID1234538913]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Onco360 is honored to be selected as a specialty pharmacy provider for Nubeqa patients," said Paul Jardina, President and CEO, Onco360. "The recent approval of Nubeqa provides another treatment option for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). As a provider of this key treatment, Onco360 will utilize its expertise in service delivery, clinical, healthcare professional and community engagement, insurance and billing, and ongoing customer service to support the highly specialized needs of CRPC patients and their physicians."

Prostate cancer is the second most commonly diagnosed malignancy and fifth leading cause of cancer in men worldwide. In 2018, an estimated 1.2 million men were diagnosed with prostate cancer and about 358,000 died from the disease worldwide. Prostate cancer results from the abnormal proliferation of cells within the prostate gland, which is part of a man’s reproductive system. It mainly affects men over the age of 50, and the risk increases with age. Treatment options range from surgery to radiation treatment to therapy using hormone-receptor antagonists (i.e. substances that stop the formation of testosterone or prevent its effect at the target location.) However, in nearly all cases, the cancer eventually becomes resistant to conventional hormone therapy.

CRPC is an advanced form of the disease, where the cancer keeps progressing even when the amount of testosterone is reduced to very low levels in the body. The field of treatment options for castration-resistant patients is rapidly evolving. However, until two years ago, there have been no FDA-approved treatment options for nmCRPC patients with prostate cancer that has not spread to other parts of the body with rising prostate-specific antigen (PSA) levels despite a castrate testosterone level. About one-third of men with nmCRPC go on to develop metastases within two years. In men with progressive nmCRPC, a short PSA doubling time is correlated with shortened time to first metastasis and death.

Manufactured by Bayer, Nubeqa was approved by the U.S. FDA on July 30, 2019 Phase III ARAMIS trial, evaluating Nubeqa plus androgen deprivation therapy (ADT), which demonstrated a highly significant improvement in the primary efficacy endpoint of metastasis-free survival (MFS), with a median of 40.4 months versus 18.4 months for placebo plus ADT (p<0.0001). Nubeqa was approved under the FDA’s Priority Review designation, which is reserved for medicines that may provide significant improvements in the safety or effectiveness of the treatment for serious conditions.

On August 21, 2019 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that the Company will participate in two investor conferences on September 5. Jigar Raythatha, CEO, will meet with investors at the Citi 14th Annual Biotech Conference at the Four Seasons Hotel in Boston (Press release, Constellation Pharmaceuticals, AUG 21, 2019, View Source [SID1234538930]). Emma Reeve, CFO, will present at the Baird Global Healthcare Conference at the InterContinental Hotel in New York at 11:25 am EDT. A live audio webcast of Ms. Reeve’s presentation and an archive for replay will be available on the Investor Relations section of Constellation’s website at View Source The audio webcast replay will be available for 90 days following the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!